US Fibrinogen Concentrates Market Outlook 2025-2035
The US fibrinogen concentrates market is set for significant growth from 2025 to 2035, driven by advances in biotechnology and increasing applications across clinical segments. Fibrinogen concentrates are plasma-derived products vital for treating bleeding disorders, acquired and congenital fibrinogen deficiencies, and are widely used in trauma care, surgical procedures, and obstetric management. Enhanced diagnostic criteria and rising awareness in healthcare contribute to greater market penetration. The sector sees rising participation from key players, advancing innovative formulations and distribution expansion. Key industry trends include collaborations for R&D, novel purification methods, and digitized supply chain channels. Strategic acquisitions and regulatory approvals are shaping competitive dynamics, as leading companies aim to capture greater value across hospital, retail, and direct tender channels. The market is forecasted to grow at a CAGR of 8.4% through 2035.
Latest Market Dynamics
Key Drivers
- Increasing prevalence of acquired and congenital fibrinogen deficiencies is fueling demand for fibrinogen concentrates in US hospitals. For example, CSL Behring expanded its portfolio in 2024 by launching new clinical programs for rapid bleeding control.
- Rising adoption in complex surgical procedures, particularly cardiac and trauma-related surgeries, supports market growth. Takeda Pharmaceutical Company introduced advanced fibrinogen products into key hospital networks in early 2025.
Key Trends
- Shift toward recombinant and plasma-derived fibrinogen concentrates, promoting higher efficacy and reduced infection risk. Octapharma AG recently announced a US launch of high-purity recombinant fibrinogen.
- Expansion of direct distribution via hospital and online channels with integrated logistics solutions. Grifols S.A. implemented new digital ordering systems for hospital pharmacies nationwide as of March 2025.
Key Opportunities
- Partnerships for R&D into novel fibrinogen formulations optimized for faster hemostasis present new growth opportunities. In 2025, Baxter International Inc. entered a joint venture to develop next-generation concentrates.
- Expanding reimbursement for fibrinogen therapies in trauma and obstetric bleeding cases. CSL Behring secured broader insurance coverage agreements in the US beginning February 2025.
Key Challenges
- Stringent regulatory requirements and delays in new product approval may slow market entry for innovative products. For instance, Kedrion S.p.A. faced FDA delays on novel animal-sourced fibrinogen concentrates in January 2025.
- Limited awareness and diagnostic challenges in rare bleeding disorders create market penetration hurdles. LFB S.A. is investing in US clinician education campaigns to boost awareness since Q1 2025.
Key Restraints
- High cost of production and pricing constraints for plasma-derived products limit access across smaller facilities. Bio Products Laboratory Ltd (BPL) reported cost-driven volume limitations in rural hospitals.
- Supply chain disruptions due to global plasma shortages hinder steady market supply. Grifols S.A. noted logistical issues impacting US deliveries in March 2025.
US Fibrinogen Concentrates Market Share by Type, 2025
In 2025, human fibrinogen concentrate constitutes the majority market share, reflecting widespread clinical acceptance and established safety profiles. Plasma-derived concentrates also hold a sizable portion, driven by their proven efficacy in critical care. Recombinant and animal-derived alternatives are gradually increasing in adoption due to innovations, though penetration remains lower than human-sourced products. The trend indicates a slow but steady diversification of the product landscape as biotechnological advances make newer options viable for complex cases.
US Fibrinogen Concentrates Market Share by Application, 2025
Surgical procedures dominate the application share within the US fibrinogen concentrates segment for 2025, owing to the critical role of hemostasis in complex and elective surgeries. Trauma management follows, reflecting the growing reliance on fibrinogen in emergency medicine. Both congenital and acquired fibrinogen deficiency treatments continue to expand steadily as awareness and diagnoses rise. Obstetric bleeding and other specialty indications collectively make up an important, albeit smaller, portion of total usage—highlighting ongoing diversification of clinical use cases.
US Fibrinogen Concentrates Market Revenue (USD Million), 2020-2035
The US fibrinogen concentrates market is projected to grow from $512 million in 2020 to $1,174 million by 2035. Steady revenue growth is attributed to expanding indications, increased hospital use, and technological advancements in product purification. The CAGR of 8.4% reflects both rising demand and continuous product innovation, particularly in complex surgical and trauma care. Larger hospital systems and integrated health networks are adopting new-generation fibrinogen products at accelerated rates.
US Fibrinogen Concentrates Market YOY Growth (%), 2020-2035
Year-over-year growth in the US fibrinogen concentrates market ranges from 4.5% to 9.2% through the forecast period. Peak growth is observed between 2023 and 2028 as product adoption expands in trauma care and surgical suites. A gradual normalization is expected post-2030, with growth sustained by next-generation product launches and broader clinical guidelines.
US Fibrinogen Concentrates Market Share by Regions (%), 2025
The Northeast region leads US fibrinogen concentrates utilization in 2025, driven by dense hospital networks and high surgical volumes. The Midwest and South follow closely, with continued investment in trauma centers and increased coverage for bleeding disorders. The West, while holding a smaller share, shows rapid growth due to metropolitan hospital expansions and new reimbursement policies for obstetric and emergency medicine applications.
US Fibrinogen Concentrates Market Players Share (%), 2025
CSL Behring, Grifols S.A., and Octapharma AG collectively hold the largest share of the US fibrinogen concentrates market in 2025. Their dominance is attributed to extensive distribution networks, broad product portfolios, and recent approvals. Smaller players are expanding their presence through innovative offerings, targeting hospital and direct tender channels. The competitive landscape is dynamic, as leading vendors continue mergers and R&D investments to secure greater market coverage. US Fibrinogen Concentrates Market Buyers Share (%), 2025
Major hospital pharmacies account for the bulk of fibrinogen concentrate purchases in 2025, given their role in supplying acute care and surgical departments. Retail pharmacies and online channels demonstrate incremental growth, particularly for outpatient and specialty care needs. Direct procurement by large health systems and government tenders represent a solid portion of volume, reflecting changing supply chain preferences and institutional purchasing strategies.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 703 |
| Regions | Northeast, Midwest, South, West |
| Segments | By Type: Human Fibrinogen Concentrate, Animal Fibrinogen Concentrate, Recombinant Fibrinogen Concentrate, Plasma-Derived Fibrinogen Concentrate, Purity-Grade Fibrinogen Concentrate, Others; By Application: Congenital Fibrinogen Deficiency, Acquired Fibrinogen Deficiency, Surgical Procedures, Trauma, Obstetric Bleeding, Others; By Technology: Pasteurization, Solvent Detergent, Filtration, Chromatography, Precipitation, Others; By Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Tenders, Distributors & Wholesalers, Others; By Organization Size: Small, Medium, Large |
| Players | CSL Behring, Grifols S.A., Octapharma AG, Sanquin, LFB S.A., Shanghai Raas, Bio Products Laboratory Ltd (BPL), Hualan Biological Engineering Inc., Kedrion S.p.A., China Biologic Products Holdings, Inc., Baxter International Inc., Takeda Pharmaceutical Company Limited, Emergent BioSolutions, Green Cross Corporation, Others |
Key Recent Developments
- April 2024: Octapharma AG received FDA approval for its recombinant fibrinogen concentrate for congenital deficiency treatment.
- June 2024: Grifols S.A. launched a digital supply chain platform for hospital pharmacy orders across the US.
- March 2024: CSL Behring announced new multi-year, multi-state insurance coverage agreements for its fibrinogen concentrate portfolio.
- May 2024: Baxter International Inc. partnered with a US biotech for next-generation fibrinogen R&D.
- February 2024: Sanquin expanded its US footprint with an advanced plasma fractionation facility focused on fibrinogen products.
